Great Lakes Advisors LLC Sells 233,540 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Great Lakes Advisors LLC cut its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 49.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 236,552 shares of the company’s stock after selling 233,540 shares during the period. Great Lakes Advisors LLC’s holdings in Pacira BioSciences were worth $4,457,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Caitlin John LLC increased its position in shares of Pacira BioSciences by 1,850.0% during the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock worth $35,000 after acquiring an additional 1,776 shares in the last quarter. Nisa Investment Advisors LLC grew its position in Pacira BioSciences by 495.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock worth $62,000 after purchasing an additional 2,749 shares in the last quarter. PNC Financial Services Group Inc. grew its position in Pacira BioSciences by 16.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock worth $68,000 after purchasing an additional 513 shares in the last quarter. Virtus Investment Advisers Inc. bought a new stake in Pacira BioSciences in the 3rd quarter worth about $98,000. Finally, Quest Partners LLC grew its position in Pacira BioSciences by 137.6% in the 3rd quarter. Quest Partners LLC now owns 9,410 shares of the company’s stock worth $142,000 after purchasing an additional 5,449 shares in the last quarter. 99.73% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Barclays upped their price objective on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a research report on Friday, February 28th. Truist Financial raised shares of Pacira BioSciences from a “sell” rating to a “hold” rating and upped their price objective for the stock from $8.00 to $25.00 in a research report on Thursday, January 30th. HC Wainwright upped their price objective on shares of Pacira BioSciences from $57.00 to $70.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $18.00 price objective on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Finally, Needham & Company LLC upped their price objective on shares of Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $27.22.

Pacira BioSciences Stock Up 0.8 %

Pacira BioSciences stock opened at $22.87 on Friday. Pacira BioSciences, Inc. has a twelve month low of $11.16 and a twelve month high of $31.67. The firm has a 50 day moving average price of $23.96 and a 200-day moving average price of $19.25. The company has a market capitalization of $1.06 billion, a P/E ratio of -11.27 and a beta of 0.86. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.